BO-653 

BO-653 is an orally active anti-atherosclerotic antioxidant that exhibits high binding affinity for LDL. BO-653 scavenges linoleic acid peroxyl radicals, inhibits lipid peroxidation during the auto-oxidation of linoleic acid, and potently suppresses LDL oxidation. BO-653 inhibits Hepatitis C Virus (HCV) replication in a concentration-dependent manner, with an IC₅₀ of 36.0 μM against the HCV subgenomic replicon in FLR3-1 cells. BO-653 demonstrates significant anti-atherosclerotic effects in various animal models, including the Watanabe heritable hyperlipidemic rabbit. BO-653 is suitable for use in research related to atherosclerosis and Hepatitis C Virus infection^[1].

BO-653 (1f) (10 min) potently inhibits linoleic acid autoxidation in a cell-free assay with an IC₅₀ of 4.6 μM^[1].
BO-653 (24 h) inhibits both SLO‑ and CuSO₄‑induced oxidation of rabbit LDL^[1].
BO-653 (1, 10 μM; 24 h) potently reduces electrophoretic mobility changes in CuSO₄-oxidized rabbit LDL, with 1 μM treatment resulting in mobility similar to native LDL^[1].
BO-653 (1, 10 μM; 24 h) potently reduces electrophoretic mobility changes in SLO-oxidized rabbit LDL^[1].
BO-653 (12-1000 μM; 72 hours) inhibits HCV replication in a concentration-dependent manner in FLR3-1 and RMT-tri cells (IC₅₀ = 36.0 μM in FLR3-1 cells) without exhibiting cytotoxicity^[2].
BO-653 (0-1000 μM; 96 hours) reduces HCV NS3 protein levels in a concentration-dependent manner in FLR3-1 cells^[2].
BO-653 (72 hours) demonstrates stronger anti-HCV activity in FLR3-1 cells than both lipophilic and hydrophilic antioxidants^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

BO-653 (1f) (250 mg/kg; p.o.; once daily; 9 days) achieves high LDL concentrations in WHHL rabbits, and confers potent resistance to LDL oxidation, supporting its efficacy as an antiatherogenic antioxidant^[1].
BO-653 (2000 mg/kg; p.o.; once daily; 14 days) shows no reduction of serum HCV RNA titer in HCV-infected chimeric uPA/SCID mice, and significantly enhances the anti-HCV effect of PEG-IFN by decreasing serum and liver HCV RNA levels^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

388.63

C₂₆H₄₄O₂

157360-23-1

OC1=C(C(C)(C)C)C2=C(OC(CCCCC)(CCCCC)C2)C=C1C(C)(C)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Tamura K, et al. Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants. J Med Chem. 2003;46(14):3083-3093.  [Content Brief]

  [2]. Yasui F, et al. Synthetic lipophilic antioxidant BO-653 suppresses HCV replication. J Med Virol. 2013 Feb;85(2):241-9.  [Content Brief]